Aardvark Therapeutics, Inc. Common Stock (AARD) — Net Asset Quality Index
Aardvark Therapeutics, Inc. Common Stock (AARD) has a Net Asset Quality Index of 91.9% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $133.23 Million minus total liabilities of $10.85 Million yields net assets of $122.38 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Aardvark Therapeutics, Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Aardvark Therapeutics, Inc. Common Stock Net Asset Quality Index Over Time (2022–2024)
This chart shows how Aardvark Therapeutics, Inc. Common Stock's Net Asset Quality Index has evolved across 3 annual periods from 2022 to 2024. As of September 2025, the index stands at 91.9%, representing net assets of $122.38 Million against total assets of $133.23 Million USD. See working capital position of Aardvark Therapeutics, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Aardvark Therapeutics, Inc. Common Stock (2022–2024)
The table below presents the year-by-year Net Asset Quality Index for Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024, covering 3 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see AARD stock market capitalisation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | -70.5% | $-54.64 Million | $77.51 Million | $132.15 Million | ▲ +259.8 pp |
| 2023 | -330.3% | $-34.80 Million | $10.54 Million | $45.34 Million | ▼ -163.7 pp |
| 2022 | -166.6% | $-27.92 Million | $16.76 Million | $44.68 Million | — |